Lead story
Time for change — how the right tooling can help overcome the challenges of tablet manufacture
In this article, Dale Natoli (president) and Kevin Queensen (technical service support), Natoli Engineering, detail the challenges faced by the R&D team when evaluating the ideal compression profile for a tablet and how the right tooling can help more
Dead good: Five poisons that save lives
Throughout the ages, numerous toxins courtesy of mother nature have been found to offer various health benefits. Here, EPM looks at five potentially deadly poisons that could be, or have been, proved by scientists to better or save lives. more
Report calls for Biomedical Catalyst scheme to continue
The UK BioIndustry Association (BIA) has published the report The Biomedical Catalyst: making the case to continue. more
Pfizer and Flynn in overcharging scandal
Pfizer and Flynn Pharma stand accused of overcharging the NHS millions for an anti-epilepsy drug. more
3D printed drug receives FDA seal of approval
The FDA has approved the first 3D printed drug, Aprecia Pharmaceuticals' Spritam. more
What's on the doping menu? Eight options...
Yet another doping story to hit the mainstream media headlines; this time concerning a data leak that, according to the Sunday Times paper, reveals the "extraordinary extent of cheating" at the world's most prestigious sporting events. more
Clean bill of health for MHRA
According to a Triennial Review, the Medicines and Healthcare products Regulatory Agency (MHRA) is well-placed to steer a global drive to improve public health. more
Another four 2015 Alzheimer’s success stories
Following hot on the heels of yesterday’s announcement that Eli-Lilly’s drug solanezumab heralded a breakthrough in the treatment of Alzheimer’s, the EPM team has done some digging and presents four additional newsworthy developments in the field. more
Eli-Lilly's drug puts brakes on Alzheimer's
A major breakthrough has been announced by Eli-Lilly in the fight against Alzheimer's. A trial of the pharma giant's drug solanezumab has shown a slowing down of the disease for patients in the early onset stages. more
West meets rising demand for electronic wearable injector
West Pharmaceutical Services has expanded production at its Scottsdale, Arizona, facility to meet rising customer demand for its SmartDose electronic wearable injector. more
Honorary Fellowship for medical pioneer
An Honorary Fellowship from the University of Wales Trinity Saint David has been awarded to Professor Christopher Wood, a pioneer of the development of new medicines for the treatment of cancer, arthritis, diabetes and Alzheimer’s disease. more
Novartis malaria treatment receives WHO prequalification
WHO prequalification has been awarded to Novartis' antimalarial medicine Coartem 80/480 mg, making it the first high strength artemisinin-based combination therapy antimalarial treatment available for public sector procurement. more
MRC and GSK venture to crack difficult disease areas
GSK and the Medical Research Council (MRC) are collaborating on an open innovation research initiative that aims to improve scientists’ understanding of inflammatory diseases that present a serious burden to patients. more
EPIRUS and Polpharma strike biosimilars deal
EPIRUS Biopharmaceuticals and Polish generics company Polpharma Group have struck a multi-product, multi-region profit-sharing deal for select EPIRUS biosimilars, representing $6 billion in innovator sales in the specified territories. more
Probiodrug funds Alzheimer’s treatment research
Probiodrug, a developer of novel therapeutic solutions to treat Alzheimer’s, will fund research at the laboratory of Cynthia Ann Lemere, PhD, a neuroscientist at the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital. more
